Latest Breaking News On - A sinclair dunlop - Page 1 : comparemela.com

Short Interest in Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Expands By 16 1%

Short Interest in Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Expands By 16 1%
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesTimothy eugene sullivanA sinclair dunlopFirst horizon advisors incNews ratings for apellis pharmaceuticals dailyNeedham companySecurities exchange commissionInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticals incApellis pharmaceuticalsJefferies financial groupApellis pharmaceuticals price performanceFinancial wealth managmentGet free reportEugene sullivanExchange commission

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Meets Expectations

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Meets Expectations
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

A sinclair dunlopRobertw bairdAdamj townsendApellis pharmaceuticalsApellis pharmaceuticals stock performanceApellis pharmaceuticals incSecurities exchange commissionInsider activity at apellis pharmaceuticalsJpmorgan chase coNews ratings for apellis pharmaceuticals dailyGoldman sachs groupEarnings history for apellis pharmaceuticalsGet free reportExchange commissionApellis pharmaceuticals daily

UBS Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $85 00

UBS Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $85 00
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesAdamj townsendRobertw bairdA sinclair dunlopRaymond jamesCharles schwab investment management incApellis pharmaceuticalsNeedham companyProfund advisorsApellis pharmaceuticals stock downSecurities exchange commissionApellis pharmaceuticals incNews ratings for apellis pharmaceuticals dailyAmerican investors coAnalyst recommendations for apellis pharmaceuticalsWynnefield capital inc

Analysts Set Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Target Price at $78 60

Analysts Set Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Target Price at $78 60
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

A sinclair dunlopRaymond jamesTimothy eugene sullivanAnalyst recommendations for apellis pharmaceuticalsGoldman sachs groupFirst horizon advisors incApellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticals incFinancial wealth managmentUs bancorpCovestor ltdStephens consultingInsider activity at apellis pharmaceuticalsApellis pharmaceuticals tradingGet free report

Apellis Pharmaceuticals (APLS) Neutral Rating Reaffirmed at Mizuho

Apellis Pharmaceuticals (APLS) Neutral Rating Reaffirmed at Mizuho
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesAdamj townsendRobertw bairdA sinclair dunlopUs bancorpAnalyst recommendations for apellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticals company profileStephens consultingCovestor ltdNeedham companyFirst horizon advisors incApellis pharmaceuticals incApellis pharmaceuticalsSecurities exchange commissionApellis pharmaceuticals stock down